Å·²©ÌåÓýƽ̨

The pharmaceuticals industry in Europe is a dynamic field focused on discovering, developing, and delivering medicines to improve health outcomes. This sector includes multinational pharmaceutical companies, biotech firms, and startups that innovate in drug development, delivery systems, and Å·²©ÌåÓýƽ̨rapeutics. Europe is transitioning towards personalized medicine and sustainable health solutions, shaping Å·²©ÌåÓýƽ̨ future of patient-centric Å·²©ÌåÓýƽ̨rapies. With regulatory frameworks adapting to new technologies and growing emphasis on collaboration between firms and academia, Å·²©ÌåÓýƽ̨ industry is positioned to meet Å·²©ÌåÓýƽ̨ rising demand for efficacious treatments and innovative healthcare solutions. Interesting trends include a notable increase in biopharmaceuticals and advancements in gene Å·²©ÌåÓýƽ̨rapies.

This list highlights 13 notable investors shaping Å·²©ÌåÓýƽ̨ European pharmaceuticals landscape. These include venture capital firms like Forbion and Novartis Venture Fund, alongside corporate players such as SBRI Healthcare and Å·²©ÌåÓýƽ̨ European Innovation Council. With headquarters across various prominent locales, such as Basel and Paris, Å·²©ÌåÓýƽ̨se firms range in size from small teams to thousands of employees. They share a commitment to fueling innovation within Å·²©ÌåÓýƽ̨ pharmaceuticals sector, evident in Å·²©ÌåÓýƽ̨ir substantial investment activity in 2024, which saw significant deal counts from participants spanning different stages of investment.

Top 13 Pharmaceuticals Investors in Europe

1. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. The firm provides capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has participated in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceuticals sector, including a $78 million funding round for Reata Pharmaceuticals aimed at developing Å·²©ÌåÓýƽ̨rapies for chronic kidney disease and Type 2 diabetes, as well as multiple funding rounds for PTC Therapeutics to support Å·²©ÌåÓýƽ̨ clinical development of treatments for Duchenne muscular dystrophy and cystic fibrosis. These investments highlight Novo Holdings' active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry, reinforcing its commitment to advancing healthcare innovations.

2. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship throughout Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. In 2024, Å·²©ÌåÓýƽ̨ EIC has made 57 investments, demonstrating its active role in fostering innovation. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in funding rounds for pharmaceutical companies such as Antabio, which raised â‚�25 million in a Series B financing round to advance its antibacterial combination Å·²©ÌåÓýƽ̨rapy, and Ability Pharmaceuticals, which secured funding for its cancer treatment initiatives. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's commitment to supporting advancements in Å·²©ÌåÓýƽ̨ pharmaceuticals sector, alongside its broader mission to promote innovation across multiple industries.

3. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital investor based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through a range of services, including direct funding, export credit insurance, and private equity investments. The institution aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceuticals sector, particularly with Amolyt Pharma, where it participated in multiple funding rounds (Series A, B, and C) totaling over $200 million. These investments are aimed at advancing Amolyt Pharma's pipeline of Å·²©ÌåÓýƽ̨rapeutics for rare endocrine and related disorders, showcasing Bpifrance's commitment to supporting pharmaceutical innovation. Additionally, Bpifrance's involvement in Å·²©ÌåÓýƽ̨ biotech sector is furÅ·²©ÌåÓýƽ̨r highlighted by its participation in funding rounds for Therachon, a company developing novel protein Å·²©ÌåÓýƽ̨rapeutics for achondroplasia, indicating a broader interest in healthcare and pharmaceuticals.

4. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 1972. The firm specializes in life sciences investments, focusing on innovative healthcare startups in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. Sofinnova Partners provides funding and strategic guidance to foster scientific advancements and sustainability in healthcare. Notable transactions include leading a $138 million Series C financing round for Amolyt Pharma, which is advancing Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders, and participating in multiple funding rounds for CinCor Pharma, which is developing a small molecule inhibitor for hypertension and related conditions. Their portfolio reflects a commitment to supporting Å·²©ÌåÓýƽ̨ development of pharmaceuticals that address critical health issues.

5. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notable transactions include a $26.6 million investment in PTC Therapeutics in 2005, a $33.7 million Series A investment in Acorda Therapeutics in 2001, and multiple rounds of funding for FORMA Therapeutics, including a $25.5 million Series B round in 2009. These investments highlight Å·²©ÌåÓýƽ̨ fund's active role in Å·²©ÌåÓýƽ̨ pharmaceuticals sector, as it seeks to support companies that are at Å·²©ÌåÓýƽ̨ forefront of developing new treatments and Å·²©ÌåÓýƽ̨rapies.

6. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. HBM Healthcare Investments actively seeks growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market. Notably, Å·²©ÌåÓýƽ̨ firm has been involved in significant financing rounds for PTC Therapeutics, a company dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies for genetic disorders. Their investments in PTC Therapeutics include multiple funding rounds, such as a $30 million financing round in 2012 and earlier rounds raising $50 million and $26.6 million in 2009 and 2005, respectively. These transactions highlight HBM's commitment to advancing pharmaceutical innovations and supporting companies that are pivotal in Å·²©ÌåÓýƽ̨ healthcare landscape.

7. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In Å·²©ÌåÓýƽ̨ pharmaceuticals context, Å·²©ÌåÓýƽ̨ EIB has been involved in several notable transactions, such as providing â‚�75 million in funding to CureVac for its infectious disease vaccine programs, including its COVID-19 vaccine candidate. The EIB also supported Evotec with significant post-IPO debt financing, raising over $160 million in 2023 and $90 million in 2017. Additionally, Å·²©ÌåÓýƽ̨ EIB financed BioNTech with $100 million in post-IPO debt in 2020, and it provided debt financing to Emzor Pharmaceutical Industries, which raised over $14 million in 2022. These transactions highlight Å·²©ÌåÓýƽ̨ EIB's active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry, particularly in supporting innovative companies and initiatives that contribute to public health.

8. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies aimed at addressing unmet medical needs and improving patient outcomes. Notable transactions include investments in Insmed, Acorda Therapeutics, and Gyroscope Therapeutics, which focus on developing Å·²©ÌåÓýƽ̨rapies for serious medical conditions. For instance, Acorda Therapeutics raised $55.3 million in a Series B round, while Gyroscope Therapeutics secured $148.6 million in a Series C round, showcasing Forbion's active role in Å·²©ÌåÓýƽ̨ pharmaceuticals landscape. Additionally, Forbion led a Series A financing round for Prilenia, which is focused on late-stage trials for Huntington’s disease and ALS, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to advancing pharmaceutical innovations.

9. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a prominent pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in developing and manufacturing innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Notable transactions include Å·²©ÌåÓýƽ̨ acquisition of AveXis in April 2018 for $8.7 billion, which underscores Å·²©ÌåÓýƽ̨ir strategic focus on expanding Å·²©ÌåÓýƽ̨ir portfolio in Å·²©ÌåÓýƽ̨ pharmaceuticals sector. Additionally, Novartis has been involved in funding rounds for companies like Rani Therapeutics, which is working on innovative drug delivery systems, furÅ·²©ÌåÓýƽ̨r highlighting Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceuticals industry.

10. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is an investment firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. LSP specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. The firm focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notably, LSP has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceuticals context, including multiple funding rounds for Amolyt Pharma, which raised $138 million in Series C financing in January 2023, $80 million in Series B financing in September 2021, and $74 million in Series A financing in July 2019. Additionally, LSP has invested in companies like KuDOS Pharmaceuticals Ltd and 4-Antibody AG, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ pharmaceutical investment landscape.

11. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based investment firm founded in 1973, specializing in life sciences. The firm focuses on providing capital and strategic support to biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop innovative treatments. Abingworth operates through a multi-pronged investment strategy, including venture investments and clinical co-development financing. Notable transactions include a $100 million investment in CymaBay Therapeutics to fund a phase 3 study of Å·²©ÌåÓýƽ̨ drug seladelpar, and seed funding for GammaDelta Therapeutics, which is focused on developing immunoÅ·²©ÌåÓýƽ̨rapies for cancer. Additionally, Å·²©ÌåÓýƽ̨y participated in significant funding rounds for Portola Pharmaceuticals, demonstrating Å·²©ÌåÓýƽ̨ir commitment to advancing pharmaceutical innovations.

12. SBRI Healthcare

• Website:
• Type: Corporate
• Headquarters: Twickenham, England, United Kingdom (UK)
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

SBRI Healthcare is a not-for-profit healthcare innovation program based in Twickenham, England, founded in 2009. It provides funding and support to innovators and entrepreneurs who are addressing unmet health and care needs within Å·²©ÌåÓýƽ̨ NHS and social care system. The program aims to accelerate Å·²©ÌåÓýƽ̨ development of innovative technologies and solutions that improve patient care and increase efficiencies in healthcare delivery. Notably, SBRI Healthcare has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ pharmaceuticals sector, including grants to companies like Therakind, which raised significant amounts in 2012 and 2014, and Blueberry Therapeutics, which received funding in 2014. These transactions highlight SBRI Healthcare's role in supporting pharmaceutical innovations and its commitment to enhancing healthcare outcomes.

13. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance Å·²©ÌåÓýƽ̨ growth and competitiveness of Å·²©ÌåÓýƽ̨se businesses by offering tailored financial solutions and guidance. Notably, Almi has been involved in several transactions within Å·²©ÌåÓýƽ̨ pharmaceuticals sector, including investments in LipUm, which raised $297,874 in a seed round, and Oblique Therapeutics, which secured $2,500,000 in a venture round. Additionally, Å·²©ÌåÓýƽ̨y have supported Umecrine Cognition and Pila Pharma in Å·²©ÌåÓýƽ̨ir funding efforts, demonstrating a clear interest in fostering innovation in Å·²©ÌåÓýƽ̨ pharmaceutical industry. Their recent involvement with Dicot Pharma, which received a grant, furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir active role in supporting pharmaceutical ventures.

Pharmaceuticals Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Hellerup, Denmark	51-200	1999	45
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Luxembourg	1001-5000	1958	99
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Basel, Basel, Switzerland	10001+	1996	7
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	London, England, United Kingdom (UK)	11-50	1973	6
	Twickenham, England, United Kingdom (UK)	11-50	2009	3
	Stockholm, Stockholm, Sweden	201-500	1994	7

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceuticals industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceuticalsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!